AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03733379 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
Study NCT03733379 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and root planing
Description: SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
Study NCT02321553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White rice
Description: white rice cake
Study NCT04239651 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: rTMS uses powerful (1.0-2.5 Tesla), focused magnetic field pulses to induce electrical currents in neural tissue noninvasively, via an inductor coil placed against the scalp.
Study NCT04239651 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Internet-Delivered Cognitive Behavior Therapy (iCBT)
Description: Cognitive behavioral therapy (CBT) is an evidence-based, structured, intensive, time-limited, symptom-focused form of psychotherapy recommended for the treatment of major depression and anxiety disorders. Internet-delivered CBT (iCBT) is structured CBT delivered via the internet.
Study NCT00319254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-606 (Bosutinib)
Description: SKI-606 (Bosutinib) 400mg once daily, for as long as tolerated or until disease progression.
Study NCT02436538 — intervention group
Intervention type: OTHER
Intervention: Anti Mullerian hormone level; Mullerian duct anomaly type
Description: Diagnosis of Mullerian duct anomaly type Clinically or by Imaging Anti-Müllerian Hormone levels
Study NCT01518842 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravitreal Bone Marrow Stem Cells
Description: One intravitreal injection of a 0.1-ml cell suspension containing around 10x106 bone marrow mononuclear stem cells(BMMSC). All treatments were performed by a single retinal specialist using topical proparacaine drops under sterile conditions (eyelid speculum and povidone-iodine). Autologous BMMSC were injected into the vitreous cavity using a 27 gauge needle inserted through the inferotemporal pars plana 3.0 - 3.5 mm posterior to the limbus. After the injection, central retinal artery perfusion was confirmed with indirect ophthalmoscopy. Patients were instructed to instill one drop of 0.3% ciprofloxacin into the injected eye four times daily for 1 week after the procedure.
Study NCT04561440 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: molecular karyotyping
Description: performed by NGS or CMA chip
Study NCT04573608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Papacarie
Description: Papacarie was introduced into the cavity using the applicator and left for 40 seconds. A blunt excavator was used to remove the softened dentin. The remaining gel was removed using a cotton pellet. When there was no change in gel color, the cavity was considered caries free. The cavity was then filled with high viscosity glass ionomer cement (GIC) in an encapsulated form (Riva Self-Cure, SDI Limited, Bayswater, VIC, Australia). A mechanical mixer was used to mix the capsule for 10 seconds, the capsule was placed into the applicator to apply the GIC into the cavity. For occluso-proximal cavities, a matrix strip with a wooden wedge was used to provide the appropriate contour of the restoration. A gloved finger was used to apply pressure on the GIC for one minute and occlusion was checked and excess material was removed
Study NCT04573608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atraumatic Restorative Treatment
Description: The tooth was cleaned with a wet cotton pellet to remove debris and plaque. Caries was removed using sharp spoon excavators (Darby-Perry #220/221, #17 DE, Hu-Friedy, Chicago, USA), followed by cleaning the cavity using a small wet cotton pellet and finally dried with a dry cotton pellet. The cavity was considered caries-free when a leather-hard texture was reached and the excavator did not stick anymore. GIC was used to restore the cavity using the same technique described for the other group.
Study NCT00555217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan
Description: 50 or 100mg/day
Study NCT00555217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: losartan
Description: 50 or 100mg/day
Study NCT00555217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lisinopril
Description: 10, 20 or 40 mg/day
Study NCT04131075 — intervention group
Intervention type: PROCEDURE
Intervention: Coronary Angiography and Multimodal Coronary Physiology Study (FFR, CFR, HMR)
Description: Coronary Angiography according to clinical indication and Multimodal Coronary Physiology Study (FFR, CFR, HMR) for functional assessment of intermediate coronary lesions
Study NCT03680183 — intervention group
Intervention type: DRUG
Intervention: Entecavir 1Mg Oral Tablet
Description: The anti-HBV treatment includes a anti-HBV antibiotics and a drug of protecting liver cells or decrease alanine aminotransferase (ALT) or aspartate transaminase (AST)
Study NCT03920943 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Measurement of temperature using non-invasive means
Description: The study intervention will involve paramedics using the TAT device to measure temperature non-invasively,the first measurements made at least 5 minutes after insertion of the temperature probe (control measurement #1), and also prior to departure from the sending facility (control measurement #2). Once the patient is in the transport vehicle and the vehicle in motion for at least 10 minutes, the paramedics will measure the patient's temperature non-invasively using the TAT. If the transport time exceeds 1 hour, additional measurements taken at 1 hour intervals for the duration of transport (up to a total of 8 hours).
Study NCT01142622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine nebulization
Description: Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity.
Study NCT01142622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine instillation
Description: Preoperative instillation of 150 mg of Ropivacaine in the peritoneal cavity.
Study NCT03733379 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metronidazole and Amoxicillin placebos
Description: Amoxicillin and metronidazole placebos thrice a day for 14 days (beginning with the first SRP session).
Study NCT03733379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole and Amoxicillin placebos
Description: Amoxicillin and metronidazole placebos thrice a day for 14 days (beginning with the first SRP session).
Study NCT03733379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole 400 mg thrice a day for 14 days (beginning with the first SRP session).
Study NCT03094533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TIVA
Description: total intravenous anesthesia with propofol
Study NCT03094533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VIMA
Description: volatile induction and maintenance anesthesia with sevoflurane
Study NCT03770117 — intervention group
Intervention type: PROCEDURE
Intervention: Prehabilitation
Description: Participants who underwent Prehabilitation will have their CT scans analysed.
Study NCT03770117 — intervention group
Intervention type: PROCEDURE
Intervention: Standard Procedure
Description: Patients who underwent a panctratoduodenectomy and did not receive any Prehabilitation will have their CT scans analysed and compared.
Study NCT04994548 — intervention group
Intervention type: PROCEDURE
Intervention: Endosocpic resection of early esophageal tumor
Description: under general anesthesia, by mucosectomy or endoscopic submucosal dissection
Study NCT00005030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 66336
Study NCT00005030 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Exploratory laparotomy and/or resection of hepatic metastases. Patients randomized to no treatment may undergo surgery at any time within 15 days of randomization. Other patients undergo surgery on days 8-15.
Study NCT02817243 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: SP2086
Description: SP2086 will be administered orally (by mouth) as 100 mg on Days 4, 5, 6, 7, and 8 and Simvastatin will be administered orally as two 20mg tablets on Days 1 and 8. Both SP2086 and Simvastatin tablets will be taken with 8 ounces (240 mL) of water.
Study NCT02817243 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Simvastatin
Description: SP2086 will be administered orally (by mouth) as 100 mg on Days 4, 5, 6, 7, and 8 and Simvastatin will be administered orally as two 20mg tablets on Days 1 and 8. Both SP2086 and Simvastatin tablets will be taken with 8 ounces (240 mL) of water.
Study NCT02717039 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Draw
Description: A one time blood draw of 150 milliliters will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture.
Study NCT03733379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin 500 mg thrice a day for 14 days (beginning with the first SRP session).
Study NCT03733379 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The probiotic contains 2 different strains of Lactobacillus reuteri: L.reuteri DSM 17938 and L. reuteri ATCC PTA 5289 each at a concentration of 1 x 108 CFU per tablet. It will be used 2 times per day by 90 days.
Study NCT03733379 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic placebo
Description: The placebo is identical to the active but without L. reuteri. The two Study Products are identical in taste, texture and shape. It will be used 2 times per day by 90 days.
Study NCT00992459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPN-100
Description: HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (\~17.4mL) delivers equivalent amount of PBA in 40 tablets of NaPBA.
Study NCT00992459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buphenyl (NaPBA)
Description: Buphenyl (NaPBA) will be the comparator drug to HPN-100 in this study.
Study NCT01511016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human recombinant leptin (metreleptin)
Description: Metreleptin was administered at a dose of 0.02 mg / kg body weight for two months, followed by a dose of 0.04 mg / kg for two more months.
Study NCT01511016 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered at a dose of 0.02 mg / kg body weight daily by subcutaneous injection for two months, followed by 0.04 mg / kg for two more months.
Study NCT04520399 — intervention group
Intervention type: OTHER
Intervention: none intervention
Description: there is no intervention in this study
Study NCT00794950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Patients are treated with a 6-week induction course of intravesical bacillus Calmette-Guerin (BCG) followed by a 2 week rest period and 4 week course of oral Sunitinib.~Patients will receive intravesical BCG (81 mg Theracys BCG in 50 ml normal saline) once weekly for 6 weeks within 6 weeks of bladder biopsy confirming high risk non-muscle invasive urothelial carcinoma. Two weeks after completion of BCG, patients will receive Sunitinib (50 mg daily) continuously for 28 days followed by a two week rest period. Patients will be reassessed with transurethral resection and urine cytology. Those with residual/recurrent disease will receive a second course identical to the initial protocol. Those with a complete response following initial or second treatment will be placed on maintenance BCG (3 week course every 6 months for 2 years). Those failing (progression, intolerance) initial/secondary treatments will be offered alternative therapy.
Study NCT03019094 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The RENOVA tibial nerve stimulation system
Description: Study participants will be implanted with the RENOVA tibial nerve stimulation system
Study NCT03413306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Eltrombopag is an oral mimetic thrombopoietin selectively binding transmembrane and juxtamembrane domains of the thrombopoietin receptor different from the binding site of thrombopoietin. Therefore it does not compete for binding with the native molecule. It is promoting thrombopoiesis and release platelets from mature megakaryocytes. Also it promotes more primitive multilineage progenitors and hematopoietic stem cells to proliferate and differentiate into thrombocytes, erythrocytes and leukocytes.
Study NCT03413306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IST (ATG + CsA)
Study NCT03413306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IST (ATG + CsA)
Study NCT01629277 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop
Description: Subcutaneous insulin delivery will be adjusted according to the computer-based algorithm advice, based on subcutaneous glucose readings
Study NCT01629277 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard insulin pump
Description: Subcutaneous insulin delivery will be administered according the standard insulin pump settings
Study NCT02458833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Plate
Description: Home Plate is a community-based, peer mentored intervention aimed at improving home food preparation practices in families with young children. Through 6 classes, this intervention explores topics related to regularly preparing healthy foods at home.
Study NCT04161976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900027
Description: LY900027 administered to participants with T1DM using CSII.
Study NCT04161976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Insulin lispro administered to participants with T1DM using CSII.
Study NCT03733379 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic placebo
Description: The placebo is identical to the active but without L. reuteri. The two Study Products are identical in taste, texture and shape. It will be used 2 times per day by 90 days.
Study NCT03503604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion, 175 mg/m2 every 3 weeks
Study NCT03503604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion, AUC=6 every 3 weeks
Study NCT03503604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV infusion, 1000 mg/m2 at day1 and day 8 every 3 weeks
Study NCT03503604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion, AUC=4 every 3 weeks
Study NCT03503604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV Infusion,180 milligrams per square meter (mg/m2) every 2 weeks
Study NCT06084299 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Tumor Infiltrating Lymphocytes
Description: Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation, and extensive expansion.
Study NCT03809689 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 68Ga-NODAGA-RGD PET/CT
Description: intravenous injection of 200 Megabecquerel (MBq) 68Ga-NODAGA-RGD followed by a whole-body acquisition after injection and one hour after injection
Study NCT03809689 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 82-Rb PET/CT as part of standard care, not a comparator
Description: 2 intravenous injections of standard dose of 82-Rb : the first followed by an at-rest acquisition, the second followed by a pharmacological myocardial stress acquisition
Study NCT04057521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care Coordination
Description: Comprehensive care coordination.
Study NCT04057521 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care Coordination
Description: Comprehensive care coordination.
Study NCT00708890 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief motivation to participate in TSG
Description: The intensive intervention will consist of a boost motivational session on follow-up alternatives and particularly on attending TSGs. Efforts will be made to connect the patients with TSG volunteers via the AA/NA contact telephone. The patients are encouraged to invite AA/NA contact persons to visit them on the ward. The patient will then have the possibility to be followed to a meeting after treatment. The patients in the intensive referral group will get a phone call four weeks after discharge. The focus of this call will be on continued motivation to attend TSGs.
Study NCT03739281 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PET/MR
Description: The included patients are imaged with PET/MR as part of the research protocol.
Study NCT03690895 — intervention group
Intervention type: OTHER
Intervention: Retrospective survival analysis
Description: Kaplan-Meier model
Study NCT00350844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: 20 mg/kg/day and dose escalating every 2 months until maximum tolerated dose.
Study NCT04247737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gluten free diet
Description: Participants keep a gluten free diet for six weeks
Study NCT02797392 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: 1) Systematic collection of information on lifestyle risk factors using questionnaire 2) Risk estimation and stratification into risk groups based on questionnaire data and information from the electronic patient record (EPR) using validated risk estimation models, 3) An individual electronic health profile with personalized advise on lifestyle change and 4) targeted preventive services incl. lifestyle counseling at the GP or the municipality for citizens at increased risk of lifestyle disease and citizens with risk behavior, respectively.
Study NCT02380911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Physicians belonging to the PCC randomized to the intervention group receive a 3-component intervention: education workshop, Educational Outreach Visits and a mHealth application uploaded to their smartphones.~In addition, 2 intervention support tools are used at the intervention clinics:~1. A web-based platform that is tailored to send SMS messages for lifestyle modification, and prompts and reminders for clinic appointments are used to improve medication adherence for patients.~2. On-site training to pharmacist assistants at the first EOV is given by physician trainers focused on counseling to improve medication adherence among patients initiating statin therapy and at each patient visit to the clinic to refill drug prescriptions.
Study NCT02744638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: probiotic yoghurt
Description: verum is a liquid probiotic yoghurt containing all four probiotics as described in the arm description. Study participants consume daily two bottles (125g) during an intervention period of four weeks.
Study NCT02744638 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: chemically acidified milk
Description: Placebo is chemically acidified milk without bacterial strains. Study participants consume daily two bottles (125g) during an intervention period of four weeks (randomly assigned).
Study NCT02744638 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Arilin
Description: 2 tablets Arilin 500mg for 7 days
Study NCT02744638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arilin
Description: 2 tablets Arilin 500mg for 7 days
Study NCT02816801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Butler-Program 2.0
Description: Internet based intervention for elderly, in which they learn how to use e-mail, video conferencing and a blog, in addition to virtual relaxation exercises.
Study NCT02100475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin degludec/liraglutide
Description: Insulin degludec/liraglutide will be given subcutaneously (s.c., under the skin) once daily in combination with metformin.~Dose individually adjusted.
Study NCT02100475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/liraglutide
Description: Insulin degludec/liraglutide will be given subcutaneously (s.c., under the skin) once daily in combination with metformin.~Dose individually adjusted.
Study NCT02100475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Dose titration of insulin aspart will be based on the respective pre-meal(s) and bedtime SMPG measured daily.
Study NCT04063969 — intervention group
Intervention type: OTHER
Intervention: Assessment of radiation safety climate
Description: The rating tool contains 28 statements which cover 5 dimensions (Leadership, communication, commitment, resources, risk awareness) of the radiation safety climate. Participants are asked to indicate on a scale of 1 (completely disagree) - 3 (neutral) - 5 (completely agree) whether they agree with each statement. A composite radiation safety climate score is calculated by adding ratings on all items.~Minimum scale score 28 - Maximum scale score 140